Trial Profile
A Phase I, Dose-finding Study of the Oral, Dual Phosphatidylinositol 3(PI3)-Kinase / Mammilian Target of Rapamycin (mTOR) Inhibitor BEZ235 in Adult Patients With Relapsed or Refractory Acute Leukemia
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 17 Feb 2023
Price :
$35
*
At a glance
- Drugs Dactolisib (Primary)
- Indications Acute myeloid leukaemia; Chronic myeloid leukaemia; Precursor cell lymphoblastic leukaemia-lymphoma
- Focus Adverse reactions
- 14 Feb 2023 Status changed from active, no longer recruiting to completed.
- 16 Aug 2017 Planned End Date changed from 1 Dec 2016 to 1 Dec 2017.
- 16 Aug 2017 Planned primary completion date changed from 1 Jun 2016 to 1 Dec 2017.